TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Relay Therapeutics ( (RLAY) ) just unveiled an announcement.
On June 8, 2025, Jami Ruben resigned from the Board of Directors and Audit Committee of Relay Therapeutics, with no disputes involved. Subsequently, on June 9, 2025, Claire Mazumdar was appointed as a Class III Director and chair of the Audit Committee. Her appointment is expected to bring strategic guidance as Relay Therapeutics prepares for its Phase 3 ReDiscover-2 trial in breast cancer, potentially impacting the company’s operations and market positioning.
The most recent analyst rating on (RLAY) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Relay Therapeutics stock, see the RLAY Stock Forecast page.
Spark’s Take on RLAY Stock
According to Spark, TipRanks’ AI Analyst, RLAY is a Neutral.
The overall stock score is primarily impacted by financial performance challenges, notably negative profitability and cash flow concerns. Technical analysis indicates short-term bullish momentum, but long-term trends remain weak. The strategic lease termination provides a positive offset through cost savings, although the valuation remains unattractive due to negative earnings.
To see Spark’s full report on RLAY stock, click here.
More about Relay Therapeutics
Relay Therapeutics is a clinical-stage precision medicine company focused on transforming the drug discovery process by integrating computational and experimental technologies. The company aims to enhance small molecule therapeutic discovery, particularly in targeted oncology and genetic disease indications.
Average Trading Volume: 2,410,803
Technical Sentiment Signal: Sell
Current Market Cap: $598.3M
See more insights into RLAY stock on TipRanks’ Stock Analysis page.